Omeros (OMER) Downgraded by ValuEngine to “Hold”

Omeros (NASDAQ:OMER) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other research firms have also recently weighed in on OMER. BidaskClub raised Omeros from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 1st. HC Wainwright set a $34.00 price target on Omeros and gave the company a “buy” rating in a report on Wednesday, August 29th. Zacks Investment Research raised Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, August 29th. Finally, Maxim Group reaffirmed a “buy” rating and set a $32.00 price target on shares of Omeros in a report on Tuesday, August 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $27.56.

OMER opened at $13.02 on Friday. The company has a market cap of $782.30 million, a PE ratio of -16.48 and a beta of 3.79. Omeros has a twelve month low of $8.36 and a twelve month high of $27.00.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.09). The firm had revenue of $4.61 million during the quarter, compared to the consensus estimate of $3.07 million. During the same quarter in the previous year, the business posted ($0.16) earnings per share. On average, sell-side analysts forecast that Omeros will post -2.48 EPS for the current year.

In related news, VP Marcia S. Kelbon sold 7,529 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $25.75, for a total transaction of $193,871.75. Following the transaction, the vice president now owns 227,645 shares in the company, valued at $5,861,858.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 12.10% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cpwm LLC increased its stake in shares of Omeros by 5.0% during the second quarter. Cpwm LLC now owns 1,074,543 shares of the biopharmaceutical company’s stock valued at $19,492,000 after acquiring an additional 51,015 shares during the period. Lesa Sroufe & Co acquired a new position in shares of Omeros during the second quarter valued at approximately $310,000. Millennium Management LLC acquired a new position in shares of Omeros during the second quarter valued at approximately $8,513,000. Ingalls & Snyder LLC increased its stake in shares of Omeros by 1.3% during the second quarter. Ingalls & Snyder LLC now owns 5,613,487 shares of the biopharmaceutical company’s stock valued at $101,829,000 after acquiring an additional 70,625 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Omeros during the second quarter valued at approximately $274,000. Institutional investors and hedge funds own 47.42% of the company’s stock.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: Leveraged Buyout (LBO)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply